SCHEMBL4119155

SCHEMBL4119155

CC(C)(C)OC(=O)NC1CC(CO[Si](C)(C)C(C)(C)C)CN(C(=O)OCc2ccccc2)C1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 1/20 0.45
KMT2A Q03164 2/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
CHRM4 P08173 1/20 0.42
HSD11B1 P28845 1/20 0.40
RORC P51449 4/20 0.40
MAPT P10636 1/20 0.39
PARP1 P09874 1/20 0.38
GRIN2B Q13224 2/20 0.38
MEN1 O00255 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
HTT P42858 1/20 0.38
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37
CTSL P07711 1/20 0.37
KDM1A O60341 1/20 0.37
MAOB P27338 1/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11912160 0.86 KMT2A (0.49) PDE4BKMT2AL3MBTL1CHRM4HSD11B1
SCHEMBL4121026 0.86 KMT2A (0.49) PDE4BKMT2AL3MBTL1CHRM4HSD11B1
SCHEMBL14428325 0.86 KMT2A (0.55) PDE4BKMT2AL3MBTL1CHRM4HSD11B1
SCHEMBL13456796 0.86 KMT2A (0.55) PDE4BKMT2AL3MBTL1CHRM4HSD11B1
SCHEMBL4126523 0.85 PDE4B (0.47) PDE4BKMT2AL3MBTL1CHRM4HSD11B1
SCHEMBL377000 0.85 PDE4B (0.47) PDE4BKMT2AL3MBTL1CHRM4HSD11B1
SCHEMBL4132831 0.85 KMT2A (0.48) PDE4BKMT2AL3MBTL1CHRM4HSD11B1
SCHEMBL2821598 0.83 PDE4B (0.54) PDE4BKMT2AL3MBTL1CHRM4HSD11B1
SCHEMBL21193584 0.83 MEN1 (0.43) KMT2ACHRM4GRIN2BMEN1NPSR1
SCHEMBL1710339 0.83 CA1 (0.39) KMT2AL3MBTL1HSD11B1PARP1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8829193-B2 PIM kinase inhibitors and methods of their use NOVARTIS AG (CH) 2014-09-09 US disclosed
US-20140249135-A1 PIM KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG (CH) 2014-09-04 US disclosed
US-8822497-B2 PIM kinase inhibitors and methods of their use NOVARTIS AG (CH) 2014-09-02 US disclosed
US-8759338-B2 Heterocyclic kinase inhibitors NOVARTIS AG (CH) 2014-06-24 US disclosed
EP-2344473-B1 HETEROCYCLIC PIM-KINASE INHIBITORS NOVARTIS AG (CH) 2014-04-16 EP disclosed
EP-2262802-B1 PIM KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG (CH) 2013-10-23 EP disclosed
EP-2132177-B1 PIM KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG (CH) 2013-07-17 EP disclosed
US-8168794-B2 Pim kinase inhibitors and methods of their use NOVARTIS AG (CH) 2012-05-01 US disclosed
US-20100216839-A1 Pim kinase inhibitors and methods of their use NOVARTIS AG (CH) 2010-08-26 US disclosed
WO-2009109576-A1 PIM KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG (CH) 2009-09-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100216839-A1 Pim kinase inhibitors and methods of their use PIM1, PIM2, PIM3 PDE4B 1716/4885KMT2A 1446/4885L3MBTL1 1858/4885
US-20140249135-A1 PIM KINASE INHIBITORS AND METHODS OF THEIR USE PIM1, PIM2, PIM3 PDE4B 2918/4885KMT2A 981/4885L3MBTL1 746/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.